1. Introduction {#Section1}
===============

Hepatocellular carcinoma (HCC) is the most common subtype of liver cancer and the third leading cause of cancer death worldwide [@B1]. Infection with hepatitis B virus (HBV) greatly increases the incidence of HCC, because it causes chronic hepatitis, liver cirrhosis, and ultimately, HCC. The estimated risk of developing HCC was observed to be 25-37-fold higher in hepatitis B surface antigen (HBsAg) carriers compared with that in non-infected patients [@B2], [@B3]. HBV infection is one of the most important pathogeneses of HCC.

Several major molecular mechanisms of hepatocarcinogenesis are caused by HBV infection. First, the HBV genome is altered by integration breakpoints. The expression of hepatitis B virus X protein (HBx) is involved in many intracellular signal transduction pathways associated with cell proliferation and cell apoptosis, and both the C-terminal truncated HBx and the C-terminal region of HBx play important roles in hepatocarcinogenesis [@B4]. Second, the integration of HBV DNA into the host genome alters the expression and function of important genes that are mostly associated with cell proliferation, differentiation, and survival, and the induction of chromosomal instability. Several recurrent HBV integration genes, including *TERT* (telomerase reverse transcriptase, *FAR2* (fatty acyl-coA reductase 2), *ITPR1* (inositol 1,4,5-trisphosphate receptor type 1, also known as IP3R1), *IRAK2* (interleukin 1 receptor associated kinase 2), *MAPK1* (mitogen-activated protein kinase 1), *MLL2* (myeloid/lymphoid or mixed-lineage leukemia 2), and *MLL4*, have been identified in recent years [@B5]-[@B7]. Additionally, the accumulation of genetic damage caused by chronic inflammation mediated by regulatory T cells contributes to the development of HCC. Traditional technologies such as PCR and northern blotting focus on known genes and small-scale sample analysis to investigate HBV integration in HCC. With the development of next-generation sequencing (NGS), many studies have achieved genome-wide surveys of HBV integration in HCC, and a great deal of data on the HBV pathogen in HCC has been obtained [@B8]-[@B11]. However, no studies have yet explored HBV integration in hepatitis samples or performed a comparison of hepatitis and HCC based on HBV sequence capture sequencing.

In this study, we conducted HBV probe-based capture assays, followed by NGS for 18 samples obtained from patients with different types of hepatitis who underwent liver biopsy, in addition to 54 HBV-positive HCCs and adjacent normal tissues, with the aim of surveying and comparing HBV integration in the disease trilogy from hepatitis to HCC. We used HBV probe-based capture technology to analyze the HBV integration profile from hepatitis to HCC. The results of the present study will increase our understanding the pathogenesis of liver cancer.

2. Materials and methods {#Section2}
========================

2.1 Tissue samples {#Section2.1}
------------------

Fifty-four HCC tissues and adjacent liver tissues were obtained via surgical excision from the livers of patients with HCC at the First Affiliated Hospital of the School of Medicine of Zhejiang University, between November 2010 and April 2012. At the same time, we collected 18 samples from patients with different types of hepatitis who underwent liver biopsy at Shenzhen People\'s Hospital at the Second Clinical Medical College of Jinan University (Table [S1](#SM0){ref-type="supplementary-material"}). The diagnoses of HCC and hepatitis were confirmed based on clinical and serological characteristics, ultrasonography (US), computed tomography (CT), magnetic resonance imaging (MRI), and pathological examination, and were consistent with the Hepatitis and Primary Liver Cancer Clinical Diagnosis and Staging Criteria. In addition, normal liver tissues from five patients were resected surgically because of hemangioma in the liver at the First Affiliated Hospital of the School of Medicine of Zhejiang University. The samples were obtained from the part of the liver that was unaffected by hemangioma and were immediately frozen in liquid nitrogen. The samples were subsequently sectioned and confirmed by histological technology. All laboratory data related to the assessment of hepatic function were within normal ranges, including serum alanine aminotransferase, aspartate aminotransferase, g-glutamyltranspeptidase, alkaline phosphatase, total bilirubin, and albumin levels, prothrombin activity, and glucose, cholesterol, and triglyceride levels. Serological tests for hepatitis B surface antigen, hepatitis C virus antibodies, and human immunodeficiency virus antibodies were negative. Neither heavy alcohol consumption nor the intake of chemical drugs was observed before surgical resection. This study was approved by the Ethics Committee of the First Affiliated Hospital (Hangzhou, China) and Shenzhen People\'s Hospital (Shenzhen, China), and informed written consent was obtained from all patients.

2.2 DNA extraction and DNA library preparation {#Section2.2}
----------------------------------------------

DNA was extracted from the tissue samples using TIANamp Genomic DNA Kits (Tiangen Biotech, Beijing, China) according to the manufacturer\'s protocols. The amount and integrity of the DNA were assayed using a Qubit® 2.0 fluorometer (Life Technologies, Carlsbad, CA, USA) and gel electrophoresis. Each DNA sample was quantified via agarose gel electrophoresis and measured using a NanoDrop system (Thermo Fisher, Waltham, MA, USA). First, 3 µg of genomic DNA was fragmented using ultrasound. The fragments were then purified, blunt-ended, A-tailed, and ligated to adaptors. Twelve cycles of PCR were then performed. Libraries with insert sizes of 350-400 bp were constructed for sequencing following the instructions provided by Illumina. After size selection in Agarose, 10 cycles of PCR were performed. The concentrations of the libraries were then quantified using a Bioanalyzer instrument (Agilent Technologies, Santa Clara, CA, USA).

2.3 HBV enrichment and sequencing {#Section2.3}
---------------------------------

The amplified DNA was captured using an HBVcap kit (MyGenostics, Baltimore, MD, USA). The hybridization probes were designed to tile along all HBV subtype sequences (A, B, C, D, E, F, G, and H). The capture experiment was conducted as follows. First, 1 μg of a DNA library was mixed with Buffer BL and the HBVcap probe (MyGenostics), and the mixture was heated at 95 °C for 7 min and 65 °C for 2 min. Next, 23 μL of prewarmed (65 °C) buffer HY (MyGenostics) was added to the mixture, which was maintained at 65 °C with a heated PCR lid for 22 hours, to allow hybridization. Then, 50 µL of MyOne beads (Thermo Fisher) were washed 3 times in 500 μL of 1× binding buffer and resuspended in 80 μL of 1× binding buffer. A 64-µL aliquot of 2× binding buffer was subsequently added to the hybrid mixture, followed by transfer to a tube containing 80 μL of MyOne beads. This mixture was mixed for 1 hour on a rotator, after which the beads were washed once with WB1 buffer at room temperature for 15 minutes and three times with WB3 buffer at 65 °C for 15 minutes. The bound DNA was then eluted using Elution Buffer, and the eluted DNA was finally amplified using the following program: 98 °C for 30 s (1 cycle); 98 °C for 25 s, 65 °C for 30 s, and 72 °C for 30 s (15 cycles); followed by 72 °C for 5 min (1 cycle). The amplicons were then purified using SPRI beads (Beckman Coulter, Inc., Fullerton, CA, USA), and paired-end 100-bp read-length sequencing was performed on a HiSeq 2000 sequencer according to the manufacturer\'s instructions (Illumina, Sa Diego, CA, USA).

2.4 Analysis of HBV integration sites {#Section2.4}
-------------------------------------

We detected HBV integration sites using local scripts. The workflow is shown in Figure [S1](#SM0){ref-type="supplementary-material"}. The raw data were first mapped to the HBV genome (NC_003977). Reads for which at least half of the bases mapped to the HBV genome were retained and then mapped to the human genome (NCBI build 37, HG19). Reads for which at least thirty percent of the bases mapped to the human genome were retained. Chimeric reads (read sequences that were partially aligned to the human genome and partially to the HBV genome, allowing 15 percent mismatch to both genomes) and mate-pair reads (allowing 10 percent mismatch to both genomes) were analyzed to detect HBV integration breakpoints. Considering errors in the experimental procedure and bioinformatics analysis, as well as the highly heterogeneous nature of tumors, we merged breakpoints within 70-bp regions in the chimeric reads, within 500-bp regions in the mate-pair reads, and within 500-bp regions in the chimeric mate-pair reads. We finally output the leftmost integration sites. HBV breakpoints with a supporting read number ≥ 2 were regarded as highly confident HBV integration sites in the subsequent analysis. HBV integration sites were annotated using Annovar with the default parameters [@B12].

2.5 PCR-based Sanger re-sequencing {#Section2.5}
----------------------------------

Aliquots of 1 μL of the supernatant from the DNA samples were used as targets in the first round of PCR amplification. PCR amplification was performed in a reaction mixture containing 0.2 μM forward and reverse primers, 10 μL of 2× PCR mix, and 1 μL of the DNA sample (water was added to bring the total volume to 20 µL). Then, 1 μL of the universal reaction was used as a template for a second round of PCR amplification. The PCR system was the same as that used in the first round of PCR. PCR primers were designed on the basis of the pairedend assembled fragment (Table [S2](#SM0){ref-type="supplementary-material"}), in which one primer was located in the human genome and the other was in the HBV genome. PCR was performed using a GeneAmp PCR System 9700 thermal cycler. For each PCR product, we performed dye terminator Sanger sequencing using an Applied Biosystems 3730 DNA analyzer.

2.6 RNA extraction and semi-quantitative RT-PCR {#Section2.6}
-----------------------------------------------

RNA was extracted from the tissues and matched normal tissue samples using the TRIzol reagent according to the manufacturer\'s instructions (Life Technologies). Quality control for the RNA samples was performed using a 2100 Bioanalyzer Instrument (Agilent Technologies) to assay the amount and integrity of the RNA. First-strand cDNA was synthesized using the PrimeScript 1^st^ Strand cDNA Synthesis Kit (Takara, Shiga, Japan) according to the manufacturer\'s instructions. Semi-quantitative RT-PCR was then performed using the cDNA as the template and the primers designed for the target regions (Table [S2](#SM0){ref-type="supplementary-material"}). H~2~O was employed as a blank control. The PCR product was detected by electrophoresis through a 2% agarose gel.

3. Results {#Section3}
==========

3.1 Sequencing of HBV DNA using HBV probe-based capture sequencing {#Section3.1}
------------------------------------------------------------------

To investigate the relationship between HBV DNA integration and hepatocarcinogenesis, we enriched potential HBV integrated fragments in 54 paired HCC and adjacent liver tissues, and in 18 liver tissues from patients with different types of hepatitis B diagnosed by the American Association for the Study of Liver Diseases (AASLD) [@B13] based on HBV probe capture technology [@B14] (Table [S1](#SM0){ref-type="supplementary-material"}). The enriched DNA was then employed for library construction and sequenced at single-base resolution using a HiSeq 2500 sequencer. We obtained a total of 497,648,760 raw reads with 100-bp-length target regions from 126 specimens, among which 70,729,110 reads completely or partially matched to the HBV genome (NC_003977). On average, 89.79% coverage with at least 10-fold read mapping was achieved for the HBV genome. The average depth of coverage was 3,188-fold (Table [S3](#SM0){ref-type="supplementary-material"}) in 126 samples. The highest depth of coverage was 16,729-fold in HCC sample 080962T, and the lowest depth of coverage was seven-fold in hepatitis sample SD090 (Table [S3](#SM0){ref-type="supplementary-material"}). After removing reads that were completely matched to the HBV genome, a total of 25,962,712 reads were mapped to the human genome reference (HG19). We finally obtained 233,339 effective reads comprising potential integration events (Figure [S1](#SM0){ref-type="supplementary-material"} and Table [S3](#SM0){ref-type="supplementary-material"}). Thus, the coverage and read depth were adequate to reliably detect HBV DNA integration.

3.2 Identification of integration breakpoints {#Section3.2}
---------------------------------------------

All 233,339 effective reads (Table [S3](#SM0){ref-type="supplementary-material"}), including chimeric reads and mate-pair reads, were used to identify integration breakpoints according to the following criteria: If some junctions supported by the chimeric reads were clustered within the range of 70bp, the only upstream junction was defined as a HBV integration breakpoint (Figure [S2](#SM0){ref-type="supplementary-material"}). The same way, if some junctions supported by the mate-pair reads were clustered within the range of 500 bp, the only upstream junction was defined as a HBV integration breakpoint (Figure [S2](#SM0){ref-type="supplementary-material"}) [@B14]. Our results identified a total of 7513 breakpoints in 126 samples, among which 2870 HBV integration breakpoints were identified in 54 HCC samples; 4466 breakpoints were identified in paired adjacent liver samples; and 177 breakpoints were identified in hepatitis samples (after filtering out breakpoints with only one read) (Table [S3](#SM0){ref-type="supplementary-material"}, Table [S4](#SM0){ref-type="supplementary-material"}). To confirm the results, we randomly selected 75 integration breakpoints for PCR and Sanger sequencing validation tests and successfully validated 85.3% (64/75) of these integration sites (Table [S5](#SM0){ref-type="supplementary-material"}). Our results suggested that the results of HBV integration detected by NGS are highly reliable.

We found that the 7513 HBV integration breakpoints were distributed across the entire human genome (Figure [1](#F1){ref-type="fig"}A). However, HBV was preferentially integrated into chromosomes 4 (P \< 0.0001), 5 (P = 0.0153), 8 (P = 0.007), 10 (P \< 0.0001), 12 (P \< 0.0001), 17 (P=0.0329), 19 (P \< 0.0001), and Y (P \< 0.0001) (experimental data compared with the expected result) (Figure [1](#F1){ref-type="fig"}C). In addition, we found no enrichment of HBV integration events in the gene body (Figure [1](#F1){ref-type="fig"}D), suggesting that HBV integration breakpoints might be randomly distributed in intragenic regions. Moreover, approximately 36.9% (2773/7513) of the breakpoints were preferentially distributed in the 1590\~1840-bp region of the HBV genome that includes the viral enhancer, X protein, and core protein coding sequences [@B15] (Figure [1](#F1){ref-type="fig"}B). Clearly, more breakpoints in the X protein (P \< 0.0001) and core protein (P\<0.0001) were observed compared with our expectations (Figure [1](#F1){ref-type="fig"}E). Our results support the view that HBV breakpoints located in these regions might facilitate the formation of HBV-human fusion genes, thus initiating hepatocarcinogenesis [@B11].

Local algorithms predicted that the integrated HBV fragments ranged in size from 28 bp to 3215 bp, and in general, long integration fragments were more frequent than short ones (Figure [2](#F2){ref-type="fig"}A). To confirm the predicted results, we used nested PCR to amplify the complete integrated HBV fragments in the human genome. In sample 807Ca, we found a 70-bp deletion at the integration breakpoint for the human genome and a 782-bp HBV fragment insertion in the human genome, as shown in Figure [2](#F2){ref-type="fig"}B. In sample 813Ca, we found a 31,913-bp deletion at the integration breakpoint for the human genome and a 106-bp HBV fragment insertion in the human genome, as shown in Figure [2](#F2){ref-type="fig"}C. Both of the above findings were consistent with the length of the HBV integration predicted by NGS.

Interestingly, the results of integration breakpoint validation using PCR-based Sanger sequencing showed structural abnormity of the human genome at loci containing HBV integration events. For example, the complementary 164-bp sequence (chr19:36207856-36208010) in the left flanking HBV integration fragment was reversed and then inserted into the right flanking region of the HBV integration fragment (chr19:36208010-36207856) compared with the reference sequence for 815Ca (HCC) (Figure [3](#F3){ref-type="fig"}A). In another case (734Ca), there was a repeat sequence of 26 bp (chr15: 90454153-90454179) in the right flanking region of the HBV integration fragment compared with the reference sequence (Figure [3](#F3){ref-type="fig"}B). Our findings suggest that the insertion of viral DNA into the host genome may induce human genome instability, which would be consistent with earlier reports [@B8],[@B15].

3.3 HBV integration breakpoints at different disease stages {#Section3.3}
-----------------------------------------------------------

We then analyzed the distribution of the number of integration breakpoints in the follow groups: normal liver, hepatitis B, adjacent liver tissues, and HCC (Figure [4](#F4){ref-type="fig"}, Table [S6](#SM0){ref-type="supplementary-material"}). All hepatitis B patients in our study were accepted for standardized treatment and were divided into four groups according to the AASLD guide [@B13], including autoimmune hepatitis, acute hepatitis B, HBeAg negative chronic hepatitis B, and HBeAg positive chronic hepatitis B (Table [S6](#SM0){ref-type="supplementary-material"}). The results showed that the mean number of HBV integrations showed an increasing trend from hepatitis to HCC (Figure [4](#F4){ref-type="fig"}A). In addition, the number of HBV integrations in the HBeAg positive chronic hepatitis B group was significantly greater than the total number of integrations in all other hepatitis B groups (P \< 0.05), demonstrating that the number of HBV integrations was positively correlated with disease progression (Figure [4](#F4){ref-type="fig"}A).

We also found that the mean number of HBV integration events in tumor samples (including HCCs and adjacent liver tissue) was greater than the mean number in the hepatitis B groups (Figure [4](#F4){ref-type="fig"}A). Interestingly, the mean number of HBV integrations was greater in adjacent liver tissues than in HCCs. However, the mean supported reads showed an increasing trend from hepatitis B (average, 2.2), adjacent liver tissues (average, 8.1), to HCCs (average, 82.1), suggesting that the relative abundance of HBV integration was highest in HCCs (Figure [4](#F4){ref-type="fig"}B).

3.4 HBV integration target genes correlate with poor prognosis {#Section3.4}
--------------------------------------------------------------

Next, we observed that the number of HBV integrations was positively associated with the titer of serum HBsAg (P \< 0.0001; Figure [5](#F5){ref-type="fig"}A). Patients with HCC with a high number of HBV integrations were generally 40-60 years old (P = 0.035, Figure [5](#F5){ref-type="fig"}B), consistent with the incidence of HCC in China in relation to age [@B1].

Genes with their transcription start sites (TSS) closest to the HBV integration sites (within 61 Mb from the integration site) were defined as integration targeted genes (ITGs) [@B15]. We then analyzed the relationship between ITGs and the prognosis of HCC patients statistically using Kaplan-Meier survival curves. The results demonstrated that individuals with HBV integrations in *LINC00293* (long intergenic non-protein coding RNA 293; disease-free survival (DFS) P = 0.008, overall survival (OS) P = 0.009), *FSHB* (follicle stimulating hormone beta subunit; DFS P = 0.05, OS P = 0.186), and *LPHN3* (latrophilin-3; DFS P = 0.493, OS P = 0.033) exhibited shorter DFS and OS than those without HBV integrations (Figure [5](#F5){ref-type="fig"}C-[5](#F5){ref-type="fig"}H), suggesting that HBV integrations correlate with poor prognosis in patients with HCC. Of course, these are preliminary results, and more samples should be collected and analyzed to confirm them.

3.5 Differentially expressed HBx-human chimeric transcripts {#Section3.5}
-----------------------------------------------------------

To validate the hypothesis that the integrated HBV fragments are expressed at the RNA level, we randomly selected 13 integration fragments located in exon regions of five genes (Figure [6](#F6){ref-type="fig"}A), which occurred only in HCC, according to the NGS analysis. RT-PCR was then performed to compare the mRNA expression between HCCs and adjacent liver tissues (Figure [6](#F6){ref-type="fig"}B). Among the 13 PCR assays we obtained eight high quality PCR products that were confirmed by Sanger sequencing (Figure [6](#F6){ref-type="fig"}B). The results revealed that 61.6% (8/13) of HBV-human DNA integration fragments were expressed at the RNA level, including four HBx integration fragments, three precore/core protein CDS, and one polymerase CDS integration fragments, and four human genes (Figure [6](#F6){ref-type="fig"}A). Interestingly, we found that the integration fragments were expressed at significantly higher levels in HCCs than in the adjacent liver tissues (Figure [6](#F6){ref-type="fig"}B). The results suggested that differentially expressed HBx-human chimeric transcripts might correlate with hepatocarcinogenesis, although more evidence is needed to confirm this hypothesis.

4. Discussion {#Section4}
=============

HBV DNA integration was first reported in 1980, which paved the way to study the mechanism of hepatocarcinogenesis at the molecular level [@B6]. Since then, researchers have used various methods to study HBV integration events, including Southern blotting, *in situ* hybridization, and PCR [@B17]-[@B20]. Recently, several groups have used whole-genome sequencing technology to detect HBV DNA integrations in hepatocellular tumor tissues and adjacent liver tissues [@B8], [@B21]. However, the cost of whole-genome sequencing technology is too high, the amount of data produced is too large, and too much time is required for the analysis of HBV DNA integration. Therefore, in the present study, we designed an HBV probe-based capture technology to analyze HBV integrations. We then used this technology to study changes in amount and extent of HBV integration between patients with hepatitis and those with HCC. Based on our data, we identified many more HBV integration events than were found in previous studies [@B8], [@B10], [@B22], [@B23], suggesting that HBV probe-based capture technology is highly effective, sensitive, and cost effective when applied at the genome-wide level to identify HBV integration events in the human genome [@B14].

Integration is not necessary for HBV replication and therefore has not routinely occurred in the natural history of HBV infection, which is quite different from the case of retroviruses [@B5]. It was previously thought that HBV DNA integration occurred at the chronic stage of HBV infection. However, research has shown that HBV DNA integration occurs at various stages of infection. Murakami et al. used Alu-PCR to analyze liver samples of 19 patients and 12 patients with acute and chronic hepatitis B, respectively, and HBV DNA integration was identified in three patients with acute hepatitis B and in all patients with chronic hepatitis [@B23]. In this study, we also found that HBV DNA integration could occur in all stages of HBV infection, including HCC (Figure [4](#F4){ref-type="fig"}A). In addition, the number of HBV integrations increased from hepatitis B to HCCs (Figure [4](#F4){ref-type="fig"}A). In the group who had experienced primary treatment failure (HBeAg positive chronic hepatitis B), there were 129 integration events in patient B9, who had the highest virus load (5.52 × 10^8^) among the group (Table [S1](#SM0){ref-type="supplementary-material"} and S6). Patient SD075 had the second highest number HBV integrations (22) and their virus load was 8.97 × 10^7^. Patient SD079T, who suffered from hepatitis B cirrhosis, had a negative virus load, but had five HBV integrations. The current findings revealed that a combination of HBV integration events and HBV load might be useful to evaluate the prognosis of hepatitis B. In addition, HBV integration events might represent a novel biomarker to define the population at high risk of HCC.

Interestingly, the number of HBV integrations in tumor samples was higher than that in hepatitis B samples (Figure [4](#F4){ref-type="fig"}A), and the mean number of HBV integrations in HCCs was lower than that in adjacent liver tissues (Figure [4](#F4){ref-type="fig"}A). However, the mean supported reads was higher in HCCs (average, 82.1) than that in the adjacent liver tissues (average, 8.1) (Figure [4](#F4){ref-type="fig"}B), suggesting that the relative abundance of HBV integration was higher in HCCs. This finding revealed that HBV integration might play a role in hepatocellular carcinogenesis in a hit-and-run manner; however, the dosage of HBV integration might be more important in hepatocarcinogenesis [@B24]-[@B26].

Ding [@B9] and Toh [@B11] concluded that HBV integration preferentially occurs in human chromosomes 17 and 10*.* However, we found that HBV integration was significantly enriched in other chromosomes, including chromosomes 4, 5, 8, 12, 19, and Y, but not in chromosomes 10 and 17 (Figure [1](#F1){ref-type="fig"}C, p \< 0.05), suggesting that our technology could identify more chromosomes that are enriched in HBV DNA integration events. Furthermore, Ding reported that the lengths of HBV integrations ranged from 34 to 1185 bp, based on FLX sequencing [@B9]. In our study, analysis of the length of the inserted HBV fragments showed that the maximum predicted length of an HBV integration was 3215 bp, except for litter fragments (Figure [2](#F2){ref-type="fig"}A), suggesting that almost the full length of the virus could be integrated into the host genome. We found that the HBV breakpoints were concentrated within the 1,590-1,840-bp region of the HBV genome, which was consistent with previous reports [@B8], [@B15]. The sequences located in these regions have been reported to participate in the integration of HBV into the host genome [@B27],[@B28].

Microhomologies (MHs) between the human genome and the HBV genome at or near integration breakpoints were also identified in our study (Figure [S3](#SM0){ref-type="supplementary-material"}). A significant enrichment of MHs was previously reported at HPV integration sites in cervical cancer [@B29]. However, we did not observe significant enrichment of MHs at HBV breakpoints (compared with random integration within the human genome) (Figure [S3](#SM0){ref-type="supplementary-material"}). This disparity may have occurred because the different viruses exhibit different integration mechanisms. Further investigation will be required to clarify the underlying mechanisms.

Our results showed that 7513 HBV integrations were distributed among 4339 genes (Table [S7](#SM0){ref-type="supplementary-material"}), which we referred to as HBV integration-targeted genes (ITGs). There were 393 recurrent ITGs found in the HCC samples and 746 ITGs were found in adjacent liver tissues samples, while only one ITG (*NAALADL2*, encoding N-acetylated alpha-linked acidic dipeptidase like 2) was found in hepatitis samples (Table [S7](#SM0){ref-type="supplementary-material"}). In total, 4339 ITGs were used for functional annotation based on Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The results revealed that the ITGs were enriched in many cancer-related pathways, including the MAPK signaling pathway, ECM-receptor interaction, and the Hedgehog signaling pathway (P \< 0.05, Figure [S4](#SM0){ref-type="supplementary-material"}A). Further KEGG analysis of the ITGs identified in hepatitis, HCC and adjacent liver tissues samples showed that the ITGs from hepatitis samples were enriched in neuroactive ligand-receptor interaction and axon guidance pathways, whereas the ITGs from HCC and adjacent liver tissues samples were enriched in cancer-related pathways (P \< 0.05, Figure [S4](#SM0){ref-type="supplementary-material"}B).

Interestingly, four genes exhibited HBV integrations in more than one-third of the HCC samples, which were *TERT* (48.1%), *MLL4* (46.3%), *PXDNL* (peroxidasin like; 42.6%) and *SNTG1* (syntrophin gamma 1; 42.6%), accounting for 76% (41/54) of the tumor samples. Among these genes, *TERT* and *MLL4* are well established as highly frequent ITGs in HCC [@B7]-[@B11]. We found 46 integration breakpoints located in the promoter region and six located in the intronic region of *TERT* (Table [S6](#SM0){ref-type="supplementary-material"}). HBx frequently integrated into the promoter of *TERT*, probably resulted in a \'cis\' effect on the transcription of *TERT* [@B8], [@B29]. In addition, there were 17 integrations in intronic regions and 47 in exonic regions of *MLL4* (Table [S6](#SM0){ref-type="supplementary-material"}). HBx frequently integrated into exon three of *MLL4*, which might generate fusion genes (Figure [6](#F6){ref-type="fig"}). Interestingly, we confirmed that the HBx-human chimeric transcripts could be expressed in HCCs using RT-PCR. As the next step of our research, we will perform additional assays to explore the relationship between HBx-human chimeric transcripts and hepatocarcinogenesis.

In summary, we systematically characterized HBV integration in patients with hepatitis and in those with HCC using HBV probe-based capture sequencing. Our findings show that HBV integrations might be a useful biomarker to monitor disease progression from hepatitis to HCC. These results provided a good foundation for future studies on the pathogenesis of liver cancer.
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![Distribution of integration breakpoints in the human and HBV genomes in 72 samples. (A) Distribution of integration breakpoints in the human genome. Each bar represents the frequency of HBV integration breakpoints at a particular locus in the human genome (hg19). Hepatocellular carcinoma (HCC), adjacent liver tissues, and hepatitis samples with HBV integrations are shown in the outer (blue), middle (brown), and inner circles (red), respectively. The scale bar indicates the number of tumors, adjacent liver tissues, and hepatitis tissues. Chromosome numbers are shown. (B) Distribution of integration breakpoints in the HBV genome. Each histogram represents the frequency of integration breakpoints at different loci in the HBV genome. HCC, adjacent liver tissues, and hepatitis samples with HBV integrations are shown in the outer (blue), middle (brown), and inner circles (red), respectively. The locations of genes encoding HBV polymerase (green), core (orange), S (red), and X (pink) proteins are shown. Genomic positions are numbered. (C) Distribution of HBV integration breakpoints in human chromosomes. The histogram shows the number of expected and observed integrations in chromosomes. P values were calculated assuming a binomial distribution. \* P \< 0.05, \*\* P \< 0.01 and \*\*\*P \< 0.001. (D) Percentages of HBV integration sites located in exon, intron, promoter, and intergenic regions of the human genome. (E) The histogram shows the number of expected and observed integration breakpoints in the HBV structures, including X proteins, polymerase, precore/core proteins, S proteins, core and e antigens, large S proteins, and intermediate-sized S proteins. P values were computed assuming a binomial distribution. \* P \< 0.05, \*\* P \< 0.01 and \*\*\*P \< 0.001.](jcav09p3225g001){#F1}

![Prediction and validation of integration fragment lengths. (A) Distribution of predicted lengths of HBV integration fragments. (B) Sanger validation of two HBV integration fragments. A 70-bp deletion at the integration breakpoint for the human genome and a 782-bp HBV fragment inserted in the human genome. (C) A 31,913-bp deletion at the integration breakpoint for the human genome and a 106-bp HBV fragment inserted into the human genome.](jcav09p3225g002){#F2}

![Sanger sequencing validation of host genome structural alterations induced by HBV integration. (A) The complementary sequence of 164 bp (chr19:36207856-36208010) in the left flanking HBV integration fragment was reversed and inserted into the right flanking HBV integration fragment (chr19:36208010-36207856) compared with the reference sequence. (B) Repeat sequence of 26 bp (chr15:90454153-90454179) in the right flanking HBV integration fragment, compared with the reference sequence.](jcav09p3225g003){#F3}

![Distribution of the number of HBV integrations in hepatitis B, adjacent liver tissue and hepatocellular carcinoma (HCC) samples. (A) Distribution of the mean number of HBV integrations in each group. (B) The mean supported reads number in hepatitis B, adjacent liver tissue, and HCC samples (P \< 0.05).](jcav09p3225g004){#F4}

![Clinical correlation analysis of HBV integration. (A) The number of HBV integration sites versus serum HBV DNA levels (cut-off set at 10^5^). P values were calculated using unpaired Student\'s *t*-tests. (B) Correlation analyses of HBV integration with the age of the affected individuals. P = 0.035, Pearson chi-square. (C, D) Kaplan-Meier survival estimates according to HBV integrations in LINC00293 (long intergenic non-protein coding RNA 293). The data are shown for the disease free survival (DFS) of patients with and without HBV integrations in LINC00293 (P = 0.008). The data are shown for the overall survival (OS) of patients with and without mutations in LINC00293 (P = 0.009); (E, F) Kaplan-Meier survival estimates according to HBV integrations in *FSHB* (follicle stimulating hormone beta subunit). The data are shown for the DFS of patients with and without HBV integrations in *FSHB* (P = 0.05). The data are shown for the OS of patients with and without mutations in *FSHB* (P = 0.186); (G, H) Kaplan-Meier survival estimates according to HBV integrations in *LPHN3* (latrophilin-3). The data are shown for the DFS of patients with and without HBV integrations in *LPHN3* (P = 0.493). The data are shown for the OS of patients with and without mutations in *LPHN3* (P = 0.033).](jcav09p3225g005){#F5}

![Location and mRNA expression of HBV-human chimeric transcripts. (A) Locations of expressed HBV-human chimeric transcripts in the HBV genome. (B) Agarose gel analysis of 13 HBV-human chimeric transcripts amplified using nested PCR technology. The PCR products were subjected to electrophoresis through a 1.3% agarose gel and visualized via ethidium bromide staining. Molecular marker lanes (m) are included. Among the 13 HBV-human DNA integration fragments, eight high quality PCR products (marked in red) were confirmed by Sanger sequencing, while the other five low quality PCR products were not validated. P indicates adjacent liver tissue and Ca indicates hepatocellular carcinoma (HCC).](jcav09p3225g006){#F6}
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